VISN padiopharmaceutical pluvicto drug

Active Awarded Last action

Contract number
36C24926N0263
Awardee
Awarding agency
Obligated
$888,455

Award facts

Contract value 18% obligated
$5,075,550.48 Current and potential, with all options
Completion date 87% complete
Current and potential, with all options
Competition
Full and Open Competition Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
East Hanover, NJ 07936, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00005 $68,589
Funding Only Action P00004 -$2,091,950
Funding Only Action P00003 $342,943
Funding Only Action P00002 · VISN radiopharmaceutical pluvicto drug tvhs INC MOD $102,883
Funding Only Action P00001 $99,687
Original award $2,366,304

About this award

Veterans Integrated Service Network 9 issued a BPA call to Advanced Accelerator Applications USA Inc. on December 20, 2025, for radiopharmaceutical supply with a ceiling value of $5,075,550.48. The call is issued under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).

Performance takes place in East Hanover, New Jersey. The call requires supply of PLUVICTO (lutetium Lu 177-based targeted radioligand therapy for prostate cancer treatment) through December 19, 2026. Advanced Accelerator Applications USA Inc., a large for-profit manufacturer of specialized radiopharmaceuticals, holds no small business designations and operates as a prime contractor without subcontract awards.

Quick answers

Who was awarded contract 36C24926N0263?

36C24926N0263 was awarded to Advanced Accelerator Applications USA Inc. by Veterans Integrated Service Network 9 (Veterans Health Administration) on December 20, 2025.

How much is contract 36C24926N0263 worth?

The government has obligated $888,455 on 36C24926N0263. Its current value, with exercised options, is $5,075,550.

Is contract 36C24926N0263 an order under another contract?

Yes. 36C24926N0263 is a BPA call under 36F79719D0169-36C24925A0031, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36C24926N0263 competed?

The extent of competition for 36C24926N0263 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award